EPO to Award Alnylam Patent on Use of RNAi Molecules in Cancer | GenomeWeb

Alnylam Pharmaceuticals said this week that the European Patent Office intends to grant the company a patent covering the use of RNAi therapeutics in cancer.

The intellectual property, EP Application No 02702247.4, is derived from the so-called Kreutzer-Limmer III patent series developed by Germany’s Ribopharma, which Alnylam acquired in 2003 and later sold off to Roche (see RNAi News, 7/12/2007).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.